1 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
2 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01205
D01205
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
3 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
4 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01205
D01205
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
5 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
6 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01205
D01205
|
Dexmedetomidine
| 13件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280 |
7 |
EDNRA
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D01227
D01227
|
Bosentan
| 11件: 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
8 |
EDNRA
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D07538
D07538
|
Bosentan
| 11件: 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
9 |
EDNRB
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer | D01227
D01227
|
Bosentan
| 11件: 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
10 |
EDNRB
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer | D07538
D07538
|
Bosentan
| 11件: 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
11 |
THRA
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway | D01011
D01011
|
Liothyronine
| 4件: 13 13, 78, 210, 212 |
12 |
THRA
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway | D08128
D08128
|
Liothyronine
| 4件: 13 13, 78, 210, 212 |
13 |
THRB
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway | D01011
D01011
|
Liothyronine
| 4件: 13 13, 78, 210, 212 |
14 |
THRB
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway | D08128
D08128
|
Liothyronine
| 4件: 13 13, 78, 210, 212 |
15 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D02229
D02229
|
Sildenafil
| 17件: 6 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 |
16 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D08514
D08514
|
Sildenafil
| 17件: 6 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 |